Atrial Fibrillation
Conditions
Brief summary
This population-based descriptive study will characterize first-time users of three NOACs (rivaroxaban, dabigatran and apixaban) in prevention of stroke in non-valvular atrial fibrillation (SPAF) patients and will assess the patterns of drug utilization in routine general practice in Colombia
Interventions
OTHERData Collection
Data will be extracted from July 2009 to the last available database extraction
Sponsors
Janssen Research & Development, LLC
Bayer
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* First prescription of NOACs (rivaroxaban, dabigatran and apixaban) in the outpatient setting. * Non valvular Atrial Fibrillation (NVAF) Patients * aged ≥18 years * at least one year of enrollment in the Audifarma database * one year since first encounter with healthcare provider will be included in the study
Exclusion criteria
* Patients with any record of index drug prescription prior to the enrolment period. * Patients who qualify as members of more than one cohort study on the same day
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Switch to another study drug | Up to 6 years | — |
| Age | At Baseline | — |
| Sex | At Baseline | — |
| Co-morbidity | At Baseline | — |
| Healthcare utilization | Up to 2 years | Primary Care Physicians visits, Outpatient visits and Hospital admissions |
| Proportion of Naive to non-naive patient | At Baseline | — |
| Dose at first prescription | Up to 6 years | — |
| Duration of treatment | Up to 6 years | — |
| Discontinuation | Up to 6 years | — |
Secondary
| Measure | Time frame |
|---|---|
| Time trends of usage of study medications | Up to 6 years |
Countries
Colombia
Outcome results
None listed